St. Paul, Minn. - Aldara (imiquimod) Cream 5 percent, a topical immune response modifier, has received U.S. Food and Drug Administration (FDA) approval for the treatment of superficial basal cell carcinoma (sBCC).
Insights into Bimekizumab 2-Year Data for PsA, nr-asSpA, and AS
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Deep Histological Margins Do Not Increase cSCC Recurrence Risk if Tumor is Fully Excised
The Cutaneous Connection: Enhancing Vitiligo Care With Nanette Silverberg, MD
Latex Gloves and the Americans With Disabilities Act
Live From Chicago: Bringing Sun Protection Awareness to Communities